MVT 105
Alternative Names: MVT-105Latest Information Update: 28 Mar 2024
Price :
$50 *
At a glance
- Originator Microvascular Therapeutics
- Class Contrast media; Diagnostic agents; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers; Ultrasonography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Uveitis
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Uveitis(Diagnosis) in USA (Parenteral)
- 14 Feb 2020 Microvascular Therapeutics has has patent protection for MVT 105 (Microvascular Therapeutics pipeline February 2020)
- 06 Feb 2020 Microvascular Therapeutics has patents pending for MVT 105 (Microvascular Therapeutics pipeline February 2020)